The experimental lung cancer drug that led Eli Lilly to spend $8 billion on a smaller biotechnology firm, Loxo Oncology, delivered impressive results Monday in a study being presented at a conference in Barcelona.

A total of 68% of 105 patients — all of whom had been previously failed by chemotherapy — saw a response after taking selpercatinib, previously known as LOXO-292, meaning that their tumors decreased in size by at least 30%. Those responses lasted for a median of 20.3 months, and the patients had progression-free survival of 18.3 months, although those numbers are based on even smaller numbers of patients and could change. The drug is only effective in the 2% of lung cancer patients with a specific gene alteration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy